Secreted protein acidic and rich in cysteine (SPARC), also known as osteonectin or BM-40,
is a matricellular protein involved in several biological processes including cell adhesion …

Leukemia represents a diverse group of hematopoietic neoplasms that can be classified into
different subtypes based on the molecular aberration in the affected cell population …

Variability in the molecular response to frontline tyrosine kinase inhibitor (TKI) therapy in
chronic myeloid leukemia may be partially driven by differences in the level of kinase …

The degradation profile of ponatinib was established during the present study by exposing it
to various stress conditions. In-silico degradation pattern of ponatinib was outlined by using …

Background Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm that harbors
the Philadelphia chromosome. Tyrosine kinase inhibitor (TKI) therapy has dramatically …

The hematopoietic neoplasm chronic myeloid leukemia (CML) is a rare disease caused by
chromosomal reciprocal translocation t (9; 22)(q34: q11) with subsequent formation of the …

In this work, fragments of isophthalic and terephthalic acids are proposed as a structural
scaffold to develop potential inhibitors of protein kinases. Novel isophthalic and terephthalic …

Background In low-income countries there is insufficient evidence on hematological, clinical,
cytogenetic and molecular profiles among new CML patients. Therefore, we performed this …

Cancer is still a major barrier to life expectancy increase worldwide, and hematologic
neoplasms represent a relevant percentage of cancer incidence rates. Tumor dependence …

The prognosis of chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI)
treatment is based on the quantification of BCR:: ABL1 fusion gene transcript copy number …